Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases. Since its inception in 2009, IMPACT has made tremendous progress in several oncology drug discovery projects including PARP inhibitors, Hedgehog pathway inhibitors and microtubule inhibitors.
IMPACT has a highly experienced management team. Dr. Ye Edward Tian, the CEO and CSO, came from Transtech Pharma in High Point, NC with 20 years of drug discovery experience. Served as Research Fellow and Associate Director, Dr. Tian played critical roles in several drug discovery projects that have advanced to clinical trials. Prior to that, he was a Senior Scientist at Pfizer in Ann Arbor, MI.Dr. Tian received his PhD in Neuroscience and Pharmacology from Michigan State University. Dr. Sui Xiong Cai, the SVP and CTO, joined the company from San Diego, CA with more than 20 years of drug discovery experience. Served as Senior Director of Chemistry at EpiCept, Maxim Pharmaceuticals and Cytovia Inc., Dr. Cai has played critical roles in several anticancer projects that have resulted in two drugs in Phase II clinical trials, and is an inventor of more than 80 US issued patents. He received his PhD in Organic Chemistry from University of Oregon. Dr. Limin Wen , the VP and CMO, served as project leader and Medical Director at Hutchison MediParm Limited, Boehringer Ingelheim, Astrazeneca and Pfizer. Dr. Wen has experience in drug development from PhI to PhIII , including medical development, project management and KOL engagement. She received her PhD in Second Military Medical University.
IMPACT has discovered two series of novel PARP inhibitors, and selected IMP4297 as a clinical candidate for development. IMPACT had submitted an IND to CFDA in Dec. 2015, and plan to initiate phase I studies in Australia in 2016. IMPACT has discovered three series of novel Hedgehog inhibitors, and selected IMP5471 as a clinical candidate for development. The company has also discovered IMP3138, a small molecular microtubule inhibitor clinical candidate, which has advantages in vitro and in vivo over paclitaxel.
IMPACT Therapeutics has successfully completed B round funding in December, 2015. The funding companies included China Summit Capital, Guangzhou YUEXIU Industrial Investment Fund, Sungent Bioventure, HAIBANG Ventures and Lilly Asia Ventures. This round of funding will be used for the clinical studies of IMP4297, and development of product pipeline. In July 2014, IMPACT has obtained A round funding from Lilly Asia Ventures, Cenova Capital and Wuxi AppTec Ventures.